Interestingly, the combination of BCL-2 and MCL-1 inhibitors has been shown to be selectively toxic melanoma24,25,41,42, acute myeloid leukemia43, and cervical cancer cells22,23, but mechanisms for this synergy remain elusive. The gene discussed is BCL2; the disease is cervical cancer.